沙库巴曲缬沙坦治疗射血分数降低心衰的5年需治疗人数估计
基于PARADIGM-HF随机双盲试验8399例射血分数≤40%的心衰患者,计算沙库巴曲缬沙坦对比依那普利在5年内预防心血管死亡或心衰住院的需治疗人数(NNT)。总体主要终点5年NNT为14,全因死亡NNT为21;亚组NNT范围分别为12–19和16–31。与安慰剂相比,ARNI的全因死亡5年NNT为11。
要点
- 沙库巴曲缬沙坦较依那普利额外预防心血管死亡或心衰住院的5年NNT为14。
- 全因死亡5年NNT为21,各亚组范围16–31。
- 与安慰剂相比,ARNI全因死亡5年NNT为11。
核心结论
- 在HFrEF患者中,沙库巴曲缬沙坦在ACEI基础上额外治疗的5年NNT与现有成熟心衰治疗相当,支持指南推荐。
研究设计与样本
- PARADIGM-HF为双盲随机对照试验,纳入8399例射血分数≤40%的HFrEF患者,随机接受沙库巴曲缬沙坦或依那普利治疗。
主要发现
- 总体主要终点(心血管死亡或心衰住院)5年NNT为14,亚组范围12–19。
- 全因死亡5年NNT为21,亚组范围16–31。
- 与安慰剂相比,ARNI全因死亡5年NNT为11。
- 其他HFrEF治疗的全因死亡5年NNT分别为:ACEI 18、ARB 24、β受体阻滞剂8、醛固酮受体拮抗剂15、ICD 14、CRT 14。
关键数值与推荐
- 主要终点5年NNT为14(总体),亚组12–19。
- 全因死亡5年NNT为21(总体),亚组16–31;对比安慰剂为11。
临床怎么用
- 对于符合条件的HFrEF患者,可依据NNT数据与患者沟通沙库巴曲缬沙坦的绝对获益,支持其作为标准治疗组成部分。
局限性
- NNT为基于试验数据的5年估算值,可能受亚组样本量及事件率影响。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
IMPORTANCE: The addition of receptor-neprilysin inhibition to standard therapy, including a renin-angiotensin system blocker, has been demonstrated to improve outcomes in patients with heart failure with reduced ejection fraction (HFrEF) compared with standard therapy alone. The long-term absolute risk reduction from angiotensin receptor neprilysin inhibitor (ARNI) therapy, and whether it merits widespread use among diverse subpopulations, has not been well described. OBJECTIVE: To calculate estimated 5-year number needed to treat (NNT) values overall and for different subpopulations for the Prospective Comparison of ARNI with Angiotensin-Converting Enzyme Inhibitor (ACEI) to Determine Impact on Global Mortality and Morbidity in Heart Failure (PARADIGM-HF) cohort. DESIGN, SETTING, AND PARTICIPANTS: Overall and subpopulation 5-year NNT values were estimated for different end points using data from PARADIGM-HF, a double-blind, randomized trial of sacubitril-valsartan vs enalapril. This multicenter, international study included 8399 men and women with HFrEF (ejection fraction, ≤40%). The study began in December 2009 and ended in March 2014. Analyses began in March 2018. INTERVENTIONS: Random assignment to sacubitril-valsartan or enalapril. MAIN OUTCOMES AND MEASURES: Cardiovascular death or HF hospitalization, cardiovascular death, and all-cause mortality. RESULTS: The final cohort of 8399 individuals included 1832 women (21.8%) and 5544 white individuals (66.0%), with a mean (SD) age of 63.8 (11.4) years. The 5-year estimated NNT for the primary outcome of cardiovascular death or HF hospitalization with ARNI therapy incremental to ACEI therapy in the overall cohort was 14. The 5-year estimated NNT values were calculated for different clinically relevant subpopulations and ranged from 12 to 19. The 5-year estimated NNT for all-cause mortality in the overall cohort with ARNI incremental to ACEI was 21, with values ranging from 16 to 31 among different subgroups. Compared with imputed placebo, the 5-year estimated NNT for all-cause mortality with ARNI was 11. The 5-year estimated NNT values were also calculated for other HFrEF therapies compared with controls from landmark trials for all-cause mortality and were found to be 18 for ACEI, 24 for angiotensin receptor blockers, 8 for β-blockers, 15 for mineralocorticoid antagonists, 14 for implantable cardioverter defibrillator, and 14 for cardiac resynchronization therapy. CONCLUSIONS AND RELEVANCE: The 5-year estimated NNT with ARNI therapy incremental to ACEI therapy overall and for clinically relevant subpopulations of patients with HFrEF are comparable with those for well-established HF therapeutics. These data further support guideline recommendations for use of ARNI therapy among eligible patients with HFrEF.
引用
- Srivastava PK, Claggett BL, Solomon SD, et al. Estimated 5-Year Number Needed to Treat to Prevent Cardiovascular Death or Heart Failure Hospitalization With Angiotensin Receptor-Neprilysin Inhibition vs Standard Therapy for Patients With Heart Failure With Reduced Ejection Fraction: An Analysis of Data From the PARADIGM-HF Trial. JAMA Cardiol. 2018. PMID: 30484837. doi:10.1001/jamacardio.2018.3957
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。